Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab plus Ipilimumab in anti-PD-1 refractory melanoma
NCT03978611Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of relatlimab in melanoma, sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants with Adverse Events (AEs), Number of Participants with Serious Adverse Events (SAEs) and 4 more. Started Dec 2021; status: terminated.
02
Drugs
relatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03978611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978611.